Navigation Links
Novel VELCADE(R) (Bortezomib) for Injection Based Four-Drug Combination Was Well Tolerated In Previously Untreated Multiple Myeloma Patients
Date:12/7/2008

drome in patients receiving VELCADE. Some of these events have been fatal. There have been reports of Reversible Posterior Leukoencephalopathy Syndrome (RPLS) in patients receiving VELCADE. RPLS is a rare, reversible, neurological disorder which can present with seizure, hypertension, headache, lethargy, confusion, blindness, and other visual and neurological disturbances. VELCADE is associated with thrombocytopenia and neutropenia. There have been reports of gastrointestinal and intracerebral hemorrhage in association with VELCADE. Transfusions may be considered. Complete blood counts (CBC) should be frequently monitored during treatment with VELCADE. Cases of acute liver failure have been reported in patients receiving multiple concomitant medications and with serious underlying medical conditions. Patients who are concomitantly receiving VELCADE and drugs that are inhibitors or inducers of cytochrome P450 3A4 should be closely monitored for either toxicities or reduced efficacy. Patients on oral antidiabetic medication while receiving VELCADE should check blood sugar levels frequently.

Adverse Reaction Data

Safety data from Phase II and III studies of single-agent VELCADE 1.3 mg/m(2)/dose twice weekly for 2 weeks followed by a 10-day rest period in 1163 patients with previously treated multiple myeloma (N=1008, not including the Phase III, VELCADE plus DOXIL(R) [doxorubicin HCl liposome injection] study) and previously treated mantle cell lymphoma (N=155) were integrated and tabulated. In these studies, the safety profile of VELCADE was similar in patients with multiple myeloma and mantle cell lymphoma.

In the integrated analysis, the most commonly reported adverse events were asthenic conditions (including fatigue, malaise and weakness) (64%), nausea (55%), diarrhea (52%), constipation (41%), peripheral neuropathy NEC (including peripheral sensory neuropathy and peripheral neuropathy aggravated)
'/>"/>

SOURCE Millennium: The Takeda Oncology Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014   Bluegrass ... focused on innovating lifesaving devices and methods for ... million in Series A financing, which was led ... from the deal will allow Bluegrass Vascular to ... Catheter System, enhance manufacturing capabilities, and proceed with ...
(Date:7/30/2014)... 30, 2014  PDL BioPharma, Inc. (PDL) (NASDAQ: ... participate in the Jefferies 2014 Boston Healthcare Summit next ... will occur on August 6, 2014 and will not ... PDL BioPharma manages a portfolio of patents and ... antibody humanization patents and license agreements with various biotechnology ...
(Date:7/30/2014)... , 30. Juli 2014 Die ... führender Anbieter im Bereich Atemtherapie- und Druckzonenprodukte, ... Landgerichts München in Deutschland anfechten werden. Dieses ... Masken ein Patent von ResMed verletze. Apex ... wichtigen Ländern gegen verschiedene Patente von ResMed ...
Breaking Medicine Technology:Bluegrass Vascular Technologies Raises $4.5M Series A Financing Led By Targeted Technology Funds 2PDL BioPharma to Participate in Jefferies 2014 Boston Healthcare Summit 2Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 2Apex setzt seinen Kampf gegen Patente für einen freien Wettbewerb fort 3
... Near-Complete Mitigation of Choroidal,Neovascularization (CNV) in an AMD ... Lpath, Inc. ,the category leader in therapeutic agents ... standard animal,model of human age-related macular degeneration (AMD). ... meeting of the,Association of Research in Vision and ...
... of SEROQUEL XR--, WILMINGTON, Del., May 22, ... analyses from a large-scale,study that investigated the ... a once-daily medicine for the,treatment of schizophrenia ... annual meeting of the American Psychiatric Association,(APA). ...
Cached Medicine Technology:Lpath Demonstrates 'First-in-Class' AMD Results With Its Lead Drug,Candidate, Sphingomab 2Lpath Demonstrates 'First-in-Class' AMD Results With Its Lead Drug,Candidate, Sphingomab 3Lpath Demonstrates 'First-in-Class' AMD Results With Its Lead Drug,Candidate, Sphingomab 4New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 2New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 3New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 4New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 5New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 6New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 7New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 8New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 9
(Date:7/30/2014)... Naperville, IL (PRWEB) July 30, 2014 ... requirements of business and technology startups is now ... leading full-service, marketing agency based in the Chicago ... categories as software and information technology (IT), services, ... more. , Marketing disciplines critical to startup ...
(Date:7/30/2014)... household income of its residents is the most important factor ... avoidable hospital visits conditions that could be better managed ... treated at an early stage, according to a report released ... , An analysis of hospital billing records and demographic ... Jersey found that as an area,s per capita income rises, ...
(Date:7/30/2014)... NY (PRWEB) July 30, 2014 The ... during the five years to 2014. Following a multiyear ... to beneficial demographic trends, the expansion of private healthcare ... IBISWorld estimates that Hearing Aid Clinics industry ... to $2.7 billion during the five years to 2014. ...
(Date:7/30/2014)... San Francisco, California (PRWEB) July 30, 2014 ... to reach USD 5,440.5 million by 2020, growing at ... according to a new study by Grand View Research, ... increasing prevalence of deafness is expected to serve this ... increasing usage rates of 100% digital hearing aid technology ...
(Date:7/30/2014)... genetic mutation linked to obesity respond differently to pictures ... do not have the genetic mutation, according to a ... of Clinical Endocrinology & Metabolism ( JCEM ). ... typically results from a combination of eating too much, ... consumption of appetizing foods that are high in calories ...
Breaking Medicine News(10 mins):Health News:Startup Marketing Practice Launched by Modern Marketing Partners 2Health News:Income is a major driver of avoidable hospitalizations across New Jersey 2Health News:Income is a major driver of avoidable hospitalizations across New Jersey 3Health News:Hearing Aid Clinics in the US Industry Market Research Report Now Available from IBISWorld 2Health News:Hearing Aid Clinics in the US Industry Market Research Report Now Available from IBISWorld 3Health News:Hearing Aids Market Analysis by Product (Behind-The-Ear Aids, In-The-Ear Aids, CIC, IIC), by Technology (Analog, Digital) Expected to Reach USD 5,440.5 Million by 2020 2Health News:Hearing Aids Market Analysis by Product (Behind-The-Ear Aids, In-The-Ear Aids, CIC, IIC), by Technology (Analog, Digital) Expected to Reach USD 5,440.5 Million by 2020 3Health News:Hearing Aids Market Analysis by Product (Behind-The-Ear Aids, In-The-Ear Aids, CIC, IIC), by Technology (Analog, Digital) Expected to Reach USD 5,440.5 Million by 2020 4Health News:Hearing Aids Market Analysis by Product (Behind-The-Ear Aids, In-The-Ear Aids, CIC, IIC), by Technology (Analog, Digital) Expected to Reach USD 5,440.5 Million by 2020 5Health News:Brain response to appetizing food cues varies among obese people 2
... HealthDay Reporter , MONDAY, Sept. 27 (HealthDay News) ... of tens of thousands of Americans at risk for ... But these medical devices have gotten a bad ... or leads, that connect the ICD to the heart ...
... and Hong Kong have conducted a comprehensive study to ... female attractiveness. The study, published in the Journal ... young, tall and long armed women were considered the ... determining factor for evolutionary, social and economic success," said ...
... Mayo Clinic researchers and their international colleagues have discovered ... subset of women when taking aromatase inhibitors to treat ... painful that many women halt their lifesaving medication. The ... Journal of Clinical Oncology . "Many women stop ...
... Ellin Holohan HealthDay Reporter , MONDAY, Sept. 27 ... predict stroke patients, risk of dying in the hospital and ... new Canadian study. Hospitals also can use the ... study author Dr. Eric Smith, assistant professor of neurology at ...
... Therapeutics, Inc. is presenting new data in five posters ... with the company,s radioprotectant Ex-RAD at the 56th Annual ... in Maui, Hawaii. In vivo studies show that ... survival versus placebo-treated groups in mice exposed to lethal ...
... The International Robotic Urology Symposium+2011 will take place Jan. ... will view numerous 3D and 2D surgeries (each morning), ... throughout the United States and abroad. , Lectures and ... and pediatrics as well as alternatives therapies to treat ...
Cached Medicine News:Health News:New Software for Defibrillators Lowers Risk of Unnecessary Shocks 2Health News:New Software for Defibrillators Lowers Risk of Unnecessary Shocks 3Health News:Unlocking the secret of beauty: Scientists discover the complexities of attractive female bodies 2Health News:Mayo collaboration finds source of breast drug side effect 2Health News:New Tool Helps Predict Stroke Patient's Risk of Death in Hospital: Study 2Health News:New Tool Helps Predict Stroke Patient's Risk of Death in Hospital: Study 3Health News:Onconova Therapeutics presents new data demonstrating radioprotection by Ex-RAD at RRS annual meeting 2Health News:Onconova Therapeutics presents new data demonstrating radioprotection by Ex-RAD at RRS annual meeting 3
Stryker Leibinger offers a variety of different Titanium Implant Systems and special instrument sets, which enable our customers to treat a wide range of indication...
Nucleus manipulator used during phacoemulsification. Used to break-up the nuclues within the capsular bag during two-handed phaco techniques. Blunt round tip, angled 40 degrees, 11mm from tip. Tip an...
... effective upgrade path that allows users to ... modularity. The potential to combine two units ... a single stimulating coil. The ability to ... the power level of each Magstim 200 ...
... The Magstim Model 200 uses a ... otherwise inaccessible nerves. World market leader in ... developed by the University of Sheffield in ... cortical hemispheric and peripheral stimulation. Our best ...
Medicine Products: